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Abstract
Purpose—We determined hormone concentrations (estradiol [E2], estrone [E1], estrone 
conjugates [E1-C], androstenedione [A], testosterone [T]) before and on anastrozole therapy 
where we also determined plasma concentrations of anastrozole and its metabolites.
Experimental—Postmenopausal women who were to receive adjuvant anastrozole for resected 
early breast cancer were studied. Pretreatment, blood samples were obtained for the acquisition of 
DNA and for plasma hormone measurements (E2, E1, E1-C, A, T). A second blood draw was 
obtained at least 4 weeks after starting anastrozole for hormone, anastrozole and metabolite 
measurements. For hormone assays, a validated bioanalytical method using gas chromatography 
negative ionization tandem mass spectrometry was used. Anastrozole and metabolite assays 
involved extraction of plasma followed by LC/MS/MS assays.
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Results—649 patients were evaluable. Pretreatment and during anastrozole, there was large 
inter-individual variability in E2, E1, and E1-C as well as anastrozole and anastrozole metabolite 
concentrations. E2 and E1 concentrations were below the lower limits of quantitation in 79% and 
70%, respectively, of patients on anastrozole therapy, but those with reliable concentrations had a 
broad range (0.627-234.0 pg/mL, 1.562-183.2 pg/mL, respectively). Considering E2, 8.9% had the 
same or higher concentration relative to baseline while on anastrozole, documented by the 
presence of drug.
Conclusions—We demonstrated large inter-individual variability in anastrozole and anastrozole 
metabolite concentrations as well as E1, E2, E1-C, A, and T concentrations before and while on 
anastrozole. These findings suggest that the standard 1 mg daily dose of anastrozole is not optimal 
for a substantial proportion of women with breast cancer.
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Introduction
The third-generation aromatase inhibitors (AIs) anastrozole, exemestane and letrozole play a 
major role in postmenopausal women with estrogen receptor (ER) positive breast cancer in 
the early (1,2) and metastatic (3) settings and have been shown to be of value as preventive 
agents in women at high risk of developing breast cancer (4,5). An American Society of 
Clinical Oncology (ASCO) Practice Guideline has recommended the use of AIs at some 
point during adjuvant endocrine therapy of early breast cancer, either as initial therapy or 
following some period of tamoxifen therapy (6).
Anastrozole is a nonsteroidal AI that was reported to maximally suppress plasma estradiol 
concentrations at doses of one and 10 mg per day (7) and Geisler et al. (8) reported 
equipotency of the one and 10 mg dose levels in terms of aromatase inhibition and 
suppression of plasma estrogen concentrations. These findings plus the results of clinical 
trials (9) led to the adoption of the one mg dose for clinical use, which was the dose 
approved by the U.S. Food and Drug Administration (FDA). However, based on the marked 
variability seen clinically in terms of outcomes and tolerability, the question can be asked 
whether the one mg daily dose is optimal for all patients.
Because this variability in clinical outcomes could be due to variability in suppression of 
estrogens, we developed a clinical study to examine anastrozole metabolism and its 
pharmacodynamic effect on estrogens, the ligand for the ER, as well as their precursors 
androstenedione and testosterone, in a large population of postmenopausal breast cancer 
patients. We have reported our findings with respect to anastrozole metabolism and 
pharmacodynamics in the first 191 patients entered on our clinical study (10) and 
demonstrated large inter-individual variation in anastrozole metabolism and its effect on 
circulating estrogens in these postmenopausal patients. In the current report, we expand this 
series to 649 women entered on our study who have hormone plasma concentrations 
(estradiol [E2}, estrone [E1], estrone conjugates [E1-C], androstenedione, testosterone), 
anastrozole and anastrozole metabolite plasma concentrations as well as genotyping data, as 
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these patients will be utilized in a series of genome-wide association studies. To our 
knowledge, this population of patients is the largest series of women with hormone and 
anastrozole determinations plus genotyping data and provides clear insights into the large 
interindividual variability in the effect of anastrozole on circulating estrogens.
Experimental
Details relating to the study design and assays for E2, E1, E1-C, androstenedione, and 
testosterone and for anastrozole and anastrozole metabolites have been presented in detail 
previously (10) and they will be briefly summarized here. The design of this clinical study 
involved postmenopausal women who were to receive anastrozole as adjuvant therapy for 
resected early stage breast cancer at Mayo Clinic, M.D. Anderson Cancer Center, or 
Memorial Sloan Kettering Cancer Center. Eligibility criteria included age of at least 18 
years, postmenopausal status, breast cancer stage I, II, or III according to the American Joint 
Committee on Cancer (AJCC) Staging Manual (Sixth Edition), a tumor that was estrogen 
receptor positive and/or progesterone receptor positive, and a planned treatment with 
anastrozole at the clinically approved dose of one mg per day. Patients could have received 
prior tamoxifen, but other prior endocrine therapy was not permitted and none of the patients 
were receiving hormone replacement therapy. Within two weeks prior to starting 
anastrozole, a blood sample was obtained for the acquisition of DNA and for pre-treatment 
hormone measurements. A second blood draw for hormone measurements, anastrozole and 
anastrozole metabolite concentrations in plasma was scheduled for at least four weeks after 
initiation of anastrozole. Patients were instructed not to take their dose of anastrozole for 
that day until after the blood was drawn. This trial (ClinicalTrials.gov study number 
NCT00283608) was performed after approval by local Institutional Review Boards in 
accordance with assurances filed with and approved by the United States Department of 
Health and Human Services. Written informed consent was provided by each patient before 
entry on study.
For the hormone assays, a validated bioanalytical method using gas chromatography 
negative ionization tandem mass spectrometry was used to measure physiologically relevant 
concentrations of the following steroids from 1.0 mL of human plasma (Taylor Technology, 
Prinston, NJ), with lower limits of quantitation in this study of: E2, 0.625 pg/mL; E1, 1.56 
pg/mL; E1-C: 6.25 pg/mL; testosterone, 25.0 pg/mL; and androstenedione, 25.0 pg/mL. 
Anastrozole and metabolite assays involved liquid-liquid extraction of plasma, followed by 
LC/MS/MS assay as previously reported (11). Although the subject of future publications, 
genotypes were determined by the RIKEN Center for Integrative Medical Science 
(Yokohama, Japan) with the Illumina Human610-Quad platform.
Results
Patients analyzed
There were 695 patients with hormone, anastrozole and anastrozole metabolite, and 
genotyping data. 46 (6.6%) patients were excluded from the analysis for the following 
reasons: 22 patients had no detectable anastrozole or anastrozole metabolite, one patient had 
no anastrozole or hydroxy-anastrozole assay performed, three patients had their “on-
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anastrozole” blood drawn less than four weeks after starting anastrozole, and 20 patients had 
a date for the hormone determinations that differed from that for the anastrozole. Thus, 649 
patients were evaluable in these analyses and their characteristics are listed in Table 1.
Anastrozole and Anastrozole Metabolites
Besides anastrozole, three metabolites were detected in plasma: anastrozole conjugates, 
hydroxy-anastrozole and hydroxy-anastrozole conjugates. Note that the triazole metabolite 
was not detected. The median plasma concentration of free anastrozole was 33.2 ng/mL 
(quartile [Q] 1: 23.5 ng/mL, Q3: 44.8 ng/mL), with a range from 0.0 to 132.1 ng/mL. The 
median plasma concentration of anastrozole conjugates was 4.70 ng/mL (Q1: 0.76 ng/mL, 
Q3: 9.07 ng/mL), with a range: 0.0 to 206.4 ng/mL. The majority of the hydroxy-anastrozole 
was recovered as conjugates. A lack of internal standards prevented absolute quantitation of 
these two metabolites, but there was a 22-fold range in the medians of the hydroxy-
anastrozole conjugate concentrations vis-à-vis the hydroxy-anastrozole concentrations.
Estradiol
Figure 1A displays the pre-anastrozole and on-anastrozole E2 plasma concentrations with 
the quartile of free anastrozole concentrations indicated. Substantial interindividual 
variability in the pre-anastrozole E2 concentrations was seen with a median value of 4.0 
pg/mL (Q1: 2.4 pg/mL, Q3: 6.5 pg/mL) and a range of 0.0 pg/mL to 62.2 pg/mL). 
Substantial interindividual variability was also seen in the on-anastrozole E2 concentrations 
with a median value of 0.0 pg/mL (Q1: 0.0 pg/mL, Q3: 0.0 pg/mL) and a range of 0.0 to 
234.0 pg/mL.
E2 concentrations were below the LLQ in 79% of patients on anastrozole therapy, but those 
with reliable detectable concentrations had a broad range (0.627 pg/mL to 234.0 pg/mL). 
Importantly, 57 of 643 patients (8.9%) patients had a stable or increased E2 level, compared 
with pre-anastrozole concentrations, which are displayed in Figure 1B where the patients at 
or above the red line of unity can be seen. These 57 patients had stable or increased E2 
concentrations despite the majority (51/57 [89%]) having detectable free anastrozole with a 
median concentration of 26.7 ng/mL (Q1: 17.5 ng/mL, Q3: 32.7 ng/mL) and a range of 0.0 
to 59.6 ng/mL, which was significantly lower than those patients who had a decrease in E2 
concentrations where the median concentration of free anastrozole was 34.2 ng/mL (Q1: 
23.8 ng/mL, Q3: 45.6 ng/mL) with a range of 0.0 ng/mL to 132.1 ng/mL (p= 1.6 E-05, rank 
sum test). The 6 patients with undetectable free anastrozole levels had detectable anastrozole 
metabolites indicating that they were taking the drug, raising the possibility that they were 
rapid metabolizers of the anastrozole. The median baseline E2 for these 57 patients was 0.0 
pg/ml (Q1: 0.0 pg/mL, Q3: 2.6 pg/mL; range: 0.0 to 66.2 pg/mL), which was significantly 
lower than for those patients who had a decrease in E2 concentrations while receiving 
anastrozole where the median concentration of E2 was 4.1 pg/mL (Q1: 2.7 pg/mL, Q3: 6.7 
pg/mL; range: 0.7 pg/mL to 42.2 pg/mL) (p=1.8 E-15, rank sum test). These 57 patients had 
a median age of 66.3 years with a range of 49.4 to 88.4 years and a median BMI of 26.3 
with a range of 16.0 to 40.6.
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Seventy-five of 643 (11.7%) patients had pre-anastrozole E2 concentrations >10 pg/mL, the 
conventional point of separating premenopausal and postmenopausal women. The median 
baseline E2 for these 75 patients was 12.8 pg/ml (Q1: 11.2 pg/mL, Q3: 16.3 pg/mL; range: 
10.2 pg/mL to 66.2 pg/mL), which was significantly higher than those patients who had pre-
anastrozole E2 concentrations ≦ 10 pg/mL (p=2.2 E-16, rank sum test). These 75 patients 
had a median age of 68.2 years with a range of 51.0 to 87.6 years and a median BMI of 35.0 
with a range of 18.3 to 53.7.
Estrone
Figure 2A displays the pre-anastrozole and on-anastrozole E1 plasma concentrations with 
the quartile of free anastrozole concentrations. Substantial interindividual variability in the 
pre-anastrozole E1 concentrations was seen with a median value of 18.6 pg/mL (Q1: 13.2 
pg/mL, Q3: 26.6 pg/mL) and a range of 0.0 to 111.0 pg/mL. Substantial interindividual 
variability was also seen in the on-anastrozole E1 concentrations with a median value of 0.0 
pg/mL (Q1: 0.0 pg/mL, Q3: 1.7 pg/mL) and a range of 0.0 to 183.0 pg/mL. E1 
concentrations were below the LLQ in 70% of patients on anastrozole therapy, but those 
with reliable detectable concentrations had a broad range (1.6 pg/mL to 183.2 pg/mL).
Thirty-seven of 639 patients (5.8%) had a stable or increased E1 level, compared with pre-
anastrozole concentrations, which are displayed in Figure 2B where the patients at or above 
the red line of unity can be seen. These 37 patients had a stable or increased E1 level despite 
the majority (31/37 [84%]) having detectable free anastrozole with a median concentration 
of 26.5 ng/mL (Q1: 0.4 pg/mL, Q3: 32.2 pg/mL; range: 0.0 to 69.6 ng/mL), which was 
significantly lower than for those patients who had a decrease in E1 concentrations where 
the median concentration of anastrozole was 34.1 ng/mL (Q1: 24.0 ng/mL, Q3: 45.7 ng/mL; 
range: 0.0 ng/mL to 132.1 ng/mL) (p= 6.7 E-05, rank sum test). The 6 patients with 
undetectable free anastrozole levels had detectable anastrozole metabolites indicating that 
they were taking the drug. The median baseline E1 for these 37 patients was 3.0 pg/ml (Q1: 
0.0 pg/mL, Q3: 18.6 pg/mL; range: 0.0 to 73.8 pg/mL), which was significantly lower than 
for those patients who had a decrease in E1 concentrations while receiving anastrozole 
where the median concentration of E1 was 18.9 pg/mL (Q1: 13.7 pg/mL, Q3: 26.9 pg/mL; 
range: 1.9 pg/mL to 111.0 pg/mL) (p=1.2 E-08, rank sum test). These 37 patients had a 
median age of 65.3 years with a range of 51.4 to 85.5 years and a median BMI of 27.2 with 
a range of 18.3 to 40.6. Twenty-seven of 36 (75%) (one patient with missing E2 value) 
patients with a stable or rising E1 on anastrozole also had a stable or rising E2 concentration 
while receiving anastrozole.
Estrone Conjugates
Figure 3 displays the pre-anastrozole and on-anastrozole E1-C plasma concentrations with 
the quartile of free anastrozole concentrations indicated in panel A. Substantial 
interindividual variability in the pre-anastrozole E1-C concentrations was seen with a 
median value of 226.0 pg/mL and a range of 0.0 to 3320.0 pg/mL. Substantial 
interindividual variability was also seen in the on-anastrozole E1-C concentrations with a 
median value of 14.2 pg/mL and a range of 0.0 to 2990.0 pg/mL. Twenty-five of 585 
patients (4.3%) had a stable or increased E1-C level, compared with pre-anastrozole 
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concentrations, and are displayed in Figure 3B where the patients at or above the red line of 
unity can be seen. These 25 patients had stable or increasing E1-C levels despite the 
majority (18/25 [72%] having detectable free anastrozole with a median concentration of 
13.3 ng/m (Q1: 0.0, Q3: 27.3 pg/mL; range of 0.0 to 98.8 ng/mL), which was significantly 
lower than for those patients who had a decrease in E1 concentrations where the median 
concentration of free anastrozole was 33.9 ng/mL (Q1: 23.9 ng/mL, Q3: 44.8 ng/mL; range: 
0.0 ng/mL to 132.1 ng/mL) (p= 1.3 E-05, rank sum test). The 7 patients with undetectable 
free anastrozole levels had detectable anastrozole metabolites indicating that they were 
taking the drug. The median baseline E1-C for these 25 patients was 127.0 pg/mL (Q1: 53.8, 
Q3: 249.0 pg/mL; range: 7.7 pg/mL to 544.0 pg/mL), which was significantly lower than for 
those patients who had a decrease in E1-C concentrations while receiving anastrozole where 
the median concentration of E1-C was 33.9 pg/mL (Q1: 23.9 pg/mL, Q3: 44.8 pg/mL; 
range: 0.0 pg/mL to 132.1 pg/mL) (p= 2.5 E-03, rank sum test). These 25 patients had a 
median age of 65.8 years with a range of 51.4 to 86.2 years and a median BMI of 27.9 with 
a range of 19.9 to 41.7.
Androstenedione
Figure 4A displays the pre-anastrozole and on-anastrozole androstenedione plasma 
concentrations and shows substantial variability in the pre-anastrozole concentrations but no 
consistent change while on anastrozole. The median androstenedione concentrations were 
423.0 pg/mL (Q1: 293.0 pg/mL, Q3: 565.5 pg/mL) and 443.0 pg/mL (Q1: 324.0, Q3: 640.0 
pg/mL), respectively, with ranges of 0.0 to 2470.0 pg/mL and 0.0 to 1600.0 pg/mL, 
respectively. In 639 patients with both pre-anastrozole and on-anastrozole concentrations, 
60% had no change or an increase in androstenedione concentrations and 40% had a 
decrease.
Testosterone
Figure 4B displays the pre-anastrozole and on-anastrozole testosterone plasma 
concentrations and again shows substantial variability in the pre-anastrozole concentrations 
but no consistent change while on anastrozole. The median testosterone concentrations were 
144.0 pg/mL (Q1: 9.5, Q3: 208.2 pg/mL) and 153.0 pg/mL (Q1: 104.0, Q3: 209.0 pg/mL), 
respectively, with ranges of 0.0 to 1230.0 pg/mL and 0.0 to 1040.0 pg/mL, respectively. In 
646 patients with both pre-anastrozole and on-anastrozole concentrations, 57% had no 
change or an increase in testosterone concentrations and 43% had a decrease.
Discussion
The most remarkable findings in our study were the substantial interindividual variability in 
baseline hormones E2, E1, and E1-C, the variability seen in the metabolism of anastrozole, 
and the pharmacodynamic effects of anastrozole on E2, E1, and E1-C. The patients enrolled 
in this study were entered from the oncology practice of three large institutions and 
represented standard practice management in that conventional therapy was employed using 
the FDA-approved dose of anastrozole (one mg daily). The importance of having blood 
anastrozole concentrations when examining these pharmacodynamic effects was clearly seen 
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from the fact that 22 patients (3.2%) had no detectable anastrozole or anastrozole metabolite 
blood levels and had to be excluded from the analysis.
Substantial interindividual variability was identified in the metabolism of anastrozole with a 
median plasma concentration of 33.2 ng/mL but a broad range, i.e., 0.0 ng/mL to 98.8 
ng/mL. This variability is currently being explored in a GWAS utilizing anastrozole and 
anastrozole metabolites as phenotypes.
A particularly remarkable finding was that a substantial proportion of patients had an 
increase in E2, E1, and E1-C while receiving anastrozole despite the majority having 
measurable levels of the active free anastrozole and the remaining having measurable 
anastrozole metabolites, indicating they had been taking the drug. This included 8.9% of 
patients for E2, 5.8% of patients for E1, and 4.3% of patients for E1-C. These patients who 
had stable or increasing E2, E1, and E1-C had significantly lower baseline concentrations of 
their respective hormones and also significantly lower concentrations of free anastrozole 
compared with the patients who had a decrease in their respective hormones. It is understood 
that patient compliance for taking drugs may be a possible confounding factor, but the 
availability of anastrozole and anastrozole metabolite levels provides assurance that patients 
were taking the anastrozole. Regarding the E2 findings in our study, the 8.9% of patients 
who had a stable or rising concentration is similar to that seen in a study of 66 patients by 
Nagao et al. (12) in which six of 66 (9%) patients treated with anastrozole had an increase in 
E2 at six or nine months after initiation of therapy. These authors concluded that in some 
breast cancer patients with ordinary menopause, E2 rebounds with AI therapy.
Also of note in our study is that, whereas E2 >10 pg/ml is generally associated with a 
premenopausal status, these levels were found in 11.7% of the patients who were judged to 
be postmenopausal by their clinicians. A review of these patients revealed a median age of 
68.2 years (range: 51.0 to 87.6 years) and a tendency to be overweight with a median BMI 
of 35.0 (range: 18.3 to 53.7). These findings indicate that there is not a definite cut-point for 
identifying a postmenopausal woman particularly since the age of patients was as high as 87 
years.
In summary, these results show marked inter-individual variability in anastrozole 
metabolism and its pharmacodynamic effects, and suggest the standard 1 mg daily dose of 
anastrozole is not optimal for a substantial proportion of women with breast cancer. This 
cohort of 649 patients is the subject of ongoing analyses of multiple GWAS with different 
phenotypes including E2, E1, E1-C, substrate/product relationships, anastrozole, anastrozole 
metabolites, and mammographic breast density. It is expected that these studies will provide 
insights into the genetic contributions to the remarkable variability identified and will 
provide focus for future studies that will help make it possible to individualize treatment of 
patients with anastrozole, a step towards precision medicine.
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A. Plasma concentrations of estradiol according to quartile of anastrozole concentration in 
breast cancer patients before and after treatment with one mg/day oral dose of anastrozole. 
Key for line color in A: black, lowest quartile; red, second quartile; yellow, third quartile; 
green highest quartile. B. Plasma concentrations of estradiol in breast cancer patients before 
(pre) and while on treatment (post) with one mg/day oral dose of anastrozole.
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A. Plasma concentrations of estrone according to quartile of anastrozole concentration in 
breast cancer patients before and after treatment with one mg/day oral dose of anastrozole. 
Key for line color in A: black, lowest quartile; red, second quartile; yellow, third quartile; 
green highest quartile. B. Plasma concentrations of estrone in breast cancer patients before 
(pre) and while on treatment (post) with one mg/day oral dose of anastrozole.
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A. Plasma concentrations of estrone conjugates according to quartile of anastrozole 
concentration in breast cancer patients before and after treatment with one mg/day oral dose 
of anastrozole. Key for line color in A: black, lowest quartile; red, second quartile; yellow, 
third quartile; green highest quartile. B. Plasma concentrations of estrone conjugates in 
breast cancer patients before (pre) and while on treatment (post) with one mg/day oral dose 
of anastrozole.
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Plasma concentrations of androstenedione (A) and testosterone (B) in breast cancer patients 
before (pre) and while on treatment (post) with one mg/day oral dose of anastrozole.
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 American Indian or Alaska Native 4 (0.6%)
 Asian 14 (2.2%)
 Black or African American 37 (5.7%)
 White 594 (91.5%)
Ethnicity
 Hispanic or Latino 55 (8.5%)
 Not Hispanic or Latino 586 (90.3%)





 1 367 (56.5%)
 2 215 (33.1%)
 3 67 (10.3%)
ER/PgR status
 Negative/Positive 4 (0.6%)
 Positive/Negative 125 (19.3%)
 Positive/Positive 519 (80.0%)
 Positive/Unknown 1 (0.2%)
HER2 status
 Negative 555 (85.5%)
 Positive 82 (12.6%)
 Unknown 12 (1.8%)
Smoking status
 No 346 (53.3%)
 Unknown 71 (10.9%)
 Yes 232 (35.7%)
Prior Chemotherapy
 No 384 (59.2%)
 Yes 265 (40.8%)
Prior tamoxifen
 No 583 (89.8%)
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Total (N=649)
 Yes 66 (10.2%)
Blood Draw Days
 N 649
 Mean (SD) 108.0(65.2)
 Median 91.0
 Range (29.0-471.0)
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Table 2




 N. patients 643 643
 Median 4.0 0.0
 Range 0.0-62.2 0.0-234.0
Estrone
 No. patients 643 643
 Median 18.6 0.0
 Range 0.0-111.0 0.0-183.2
Estrone conjugates
 No. patients 585 585
 Median 226.0 14.2
 Range 0.0-3320.0 0.0-2990.0
Androstenedione
 No. patients 639 639
 Median 423.0 443.0
 Range 0.0-2470.0 0.0-1600.0
Testosterone
 No. patients 646 646
 Median 144.0 153.0
 Range 0.0-1230.0 0.0-1040.0
Steroids. Author manuscript; available in PMC 2016 July 01.
